Open AccessA Summary of the Endocrine Society Clinical Practice Guidelines on Congenital Adrenal Hyperplasia due to Steroid 21-Hydroxylase Deficiency
Author(s) -
PhyllisW Speiser,
Ricardo Azziz,
LaurenceS Baskin,
Lucia Ghizzoni,
TerryW Hensle,
DeborahP Merke,
HeinoFL Meyer-Bahlburg,
WalterL Miller,
VictorM Montori,
SharonE Oberfield,
Martin Ritzén,
PerrinC White
Publication year - 2010
Publication title -
international journal of pediatric endocrinology/international journal of pediatric endocrinology
Language(s) - English
Resource type - Journals
eISSN - 1687-9856
pISSN - 1687-9848
DOI - 10.1186/1687-9856-2010-494173
Subject(s) - congenital adrenal hyperplasia , medicine , 21 hydroxylase , endocrine system , clinical practice , pediatrics , endocrinology , family medicine , hormone
Steroid 21-hydroxylase deficiency accounts for about 95% of cases of congenital adrenal hyperplasia (CAH). Newborns are currently being screened for the classical forms of this disease throughout the United States and in 12 other countries. As such, it seems important to develop the best practice guidelines for treating not only infants and children, but affected adults as well. This report gives a brief overview of the most recent expert opinion and clinical practice guidelines for CAH as formulated by The Endocrine Society Task Force.